News

  • Gentag Announces Lab-on-a-Chip (LOC) Patent For Diagnostics With Cell Phones (NFC)

    October 18, 2016

    This new platform could make accurate point-of-care diagnostics instantly available to anyone with a cell phone.

     WASHINGTON, DC, October 18, 2016 — /PRNewswire/ —

    Gentag, Inc. is pleased to announce the issuance of U.S. Patent No. 9,470,699. This is the company’s seventy-sixth issued patent in the area of diagnostics with cell phones. This new patent, which covers both advanced biomarker and DNA-level detection with smartphone-based diagnostics, further enhances the company’s already significant intellectual property holdings of near field communication (NFC) mobile phone sensor technologies, including patents on wearable NFC diagnostic skin patches, immunoassays, lab-on-a-chip (LOC), printable e-noses and microelectromechanical systems (MEMS).

    The new patent covers quantitative diagnostic tests that could be carried out anywhere – no lab, or costly lab work, needed – using NFC-enabled mobile phones. With LOC technology, combined with other Gentag intellectual properties, multiple diagnostic tests could be possible within minutes using a small blood or urine sample. The new Gentag patent combines NFC, LOC, sensors and microfluidics, enabling virtually any biomarker or DNA test to be conducted with an NFC mobile phone. Biomarkers, tiny biological “signature” molecules, indicate the presence of specific proteins, diseases or medical conditions, including cancer.

    This wireless platform technology, which can be tailored to measure almost any protein, biomarker or DNA, is disposable. Examples of potential applications include: on-the-spot detection of a medical condition, companion diagnostics for problematic drug interactions, or the detection of specific allergens in foods. The technology could further be used for drug mixing and delivery, rapid lab tests, forensics and a multiplicity of applications where minuscule amounts of fluids and chemistries need to be mixed and controlled with precision. The use of NFC and cell phones ensures that the technology could become widely available to anyone.

    Because of its low cost and ease of use, the technology could revolutionize diagnostics. “We believe that the combination of the LOC technology with NFC sensors and proprietary chemistries will allow accurate diagnostic testing to become available to anyone with access to a cell phone,” stated Dr. John P. Peeters, Gentag’s founder and Chief Executive.

    Gentag’s early NFC patents, filed in 2003 and 2004, address the uses of disposable NFC sensor devices, including wearable skin patches, and associated NFC readers in devices such as mobile phones. The new allowance complements the previously announced NFC diagnostic skin patch, immunoassay and e-nose patents.

    The technology is currently available for licensing.  For more information, please contact Scott Chesky in New York at 646-937-6550 or gentag@cheskypartners.com.

     About Gentag

    Gentag is pioneering the use of disposable, ultrathin wearable and immunoassay biosensors that can be read with NFC-enabled devices, which will make healthcare and consumer diagnostics more affordable and accessible to all worldwide. The company’s groundbreaking work will revolutionize not only medical applications, but also location-based services and the detection of environmental threats in food, homes and workplaces everywhere. Gentag’s first wireless sensor network patent was filed in 1997. All Gentag NFC patents are held by Altivera, LLC, a Maryland company operated by Gentag and owned by its shareholders.

    Gentag’s powerful IP and partnerships are at work for a smarter, more connected world.

    For more information, visit http://gentag.com/ and follow Gentag on Twitter (@gentagInc).

    10
  • Gentag and Security First Corp. Sign Agreement to Secure NFC Sensor Transactions

    January 12, 2016

    Can the IoT Actually Be Secure? These Two Companies Say Yes

    Gentag and Security First Corp. Sign Agreement to Secure NFC Sensor Transactions

    WASHINGTON, DC and RANCHO SANTA MARGARITA, CA–(Marketwired – Jan 11, 2016) –  Gentag Inc. and Security First Corp. have announced an agreement to secure NFC and sensor transactions for the Internet of Things (IoT). California-based Security First Corp.’s patented cryptographic splitting technology called SPx™ (SecureParser® extended), which uses multi-factor secret sharing, will be used to secure NFC and other IoT sensor solutions for personal identification, contactless payments, healthcare, fitness, and home applications. By leveraging both companies’ expertise, security standards will advance exponentially for cell phone NFC or Bluetooth-based sensor transactions, which are forecasted to experience explosive growth in the coming decade. Application examples include diabetes monitoring, smart medication, nutrition and fitness, and authentication.

    Security First Corp.’s cryptographic splitting technology is the only security technology in the marketplace today which offers all the key components of data security; confidentiality, integrity and availability in one solution. It can be embedded directly into the sensors, or overlaid with any existing Android NFC reader, such as a smartphone or tablet. The company’s SPx technology provides a simple way to protect and control access to any data, whether at rest or in motion across diverse systems. The technology randomly splits (scrambles) the data into secure shares, authenticates those data shares, and then transmits those shares as unreadable pieces so they can be stored in multiple locations.

    SPx technology is government certified to protect the highest level of classified data. Additionally, it is Federal Information Processing Standard (FIPS) 140-2 level 1 and 2 certified, with multiple FIPS certifications. It is also Common Criteria EAL4+ compliant and has passed EAL4+ platform certification.

    Initial focus areas are medical, diagnostic and pharmaceutical applications. Gentag holds worldwide patents in the areas of wearable and biomarker sensors that can be read with NFC- enabled devices, such as most smartphones.

    The number of sensor-based IoT transactions is expected to explode over the next decade, causing disruption across multiple industries. Some predictions are that there will be one trillion sensor transactions by 2020. As the number of transactions and the sensitivity of the information exchanged increases, security and data concerns will be increasingly important. “By encrypting at the level of the sensor or ASIC, optimal security is assured,” said Dr. John P. Peeters, president and chief executive officer of Gentag. “Certain sectors, including authentication and healthcare, are going to see more disruption than others. Healthcare in particular will entail the exchange of sensitive information, and it is imperative that the information is kept secure.”

    An example of a patented Gentag application is using NFC skin patches to measure levels of ultraviolet radiation (UV) for skin cancer prevention. A mother can use the patch directly with her cell phone to verify the sun exposure level of her child for the day or over several days. Whether the measurements are for sun exposure, temperature, diabetes or drug delivery, such seemingly small sensor transactions are private and should be secured to protect the mother’s identity and keep her location information and that of her children secure, among other considerations.

    “Safeguarding patient data is a top concern for the medical devices industry. Now with the addition of SPx technology in Gentag products, users can rest assured that the information gathered is protected,” said Mark O’Hare, president and chief executive officer of Security First Corp. “We look forward to working with Gentag to provide a secure solution for NFC devices.”

    The combined NFC and SPx safety technology is available immediately for a number of market applications. For a demonstration of the technology or for licensing, contact info@gentag.com or sales@securityfirstcorp.com.

    About Gentag

    Gentag is pioneering the use of disposable, ultrathin wearable biosensors that can be read with NFC-enabled devices, which will make healthcare and consumer diagnostics more affordable and accessible to all worldwide. The company’s groundbreaking work will revolutionize not only medical applications, but also location-based services and the detection of environmental threats in food, homes and workplaces everywhere.

    Gentag’s powerful IP and partnerships are at work for a smarter, more connected world.

    For more information, visit http://gentag.com/ and follow Gentag on Twitter (@gentagInc).

    About Security First

    Founded in 2002, Security First Corp., is a privately held company headquartered in Rancho Santa Margarita, California. As the industry leader in software-defined data security technology, the company holds more than 268 patents and patent applications. It is committed to bringing advanced, data-centric security solutions that solve many of the new challenges brought by the tremendous growth of digital information. SPxSHARC™, the company’s latest data security product, protects information down to the bit level, ensuring data is safe within a network that has been breached, misconfigured or has failed to apply security updates. Products built around this unique SPx™ core technology are currently protecting exabytes of data for customers in government, communications, defense and military applications. For more information, visit
    www.securityfirstcorp.com.

    Contact Information

    15
  • “Sweating the big stuff” – Gentag mentioned in September 19th print edition of The Economist

    September 18, 2015

    Gentag’s pain-free wearable diabetes patch technology was mentioned in an article that appeared in the September 19th print edition of The Economist.

    For the full article, please visit: http://www.economist.com/news/science-and-technology/21664942-patches-skin-can-analyse-sweat-and-monitor-glucose-sweating-big-stuff

    16
  • Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes

    March 4, 2015

    ROCHESTER, Minn. — Mayo Clinic and Gentag, Inc. have reached an agreement to develop the next generation of wearable biosensors designed to fight obesity and diabetes.

    “We are hoping that this technology will be game-changer. These patch biosensors may help us reduce global obesity and diabetes,” says James Levine, M.D., Ph.D., a Mayo Clinic endocrinologist and obesity researcher. “They are accurate, inexpensive, and can be integrated into the care people receive.”

    A first-of-its-kind, the wearable patch sensors are the size of a small bandage, and are designed to be painless, wireless and disposable. In the bandage is a sensor that communicates via a closed-loop diabetes management system which is compatible with cell phones. The system will allow researchers to monitor movement and develop treatments for obesity and related conditions.

    A joint intellectual property (IP) agreement with Mayo Clinic made the research and development of this tool possible. Gentag signed a patent pooling agreement with Mayo Clinic for the management of IP related to wearable patch sensor and wireless communication technologies. Under the agreement, certain patent rights and technologies of both Mayo Clinic and Gentag will be combined and commercialized.

    The two firms will collaborate with third parties under license to bring Mayo Clinic’s expertise in medicine and clinical practices to the public by the development of the next generation of wearable skin patch technologies from Gentag in the areas of diabetes and obesity management. More than 50 issued patents and technologies are being offered for licensing under the agreement.

    “We are thrilled to be cooperating with the Mayo Clinic on these amazing new wireless technologies,” says John P. Peeters, Ph.D., the CEO of Gentag. “We look forward to working with the medical device community to get this technology into the marketplace.”

    Additionally, Mayo’s Micro-Miniature Transceiver chip will be combined with Gentag’s radar-responsive tag technology and integrated under license to create a new type of communication chip that will combine Near Field Communication (NFC), Body Area Networks (BAN), as well as long-range wireless communication and geolocation.

    About Mayo Clinic

    Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://mayocl.in/1ohJTMS, or http://newsnetwork.mayoclinic.org/.

    About Gentag

    Gentag, Inc. is pioneering the use of disposable, ultrathin, wearable and immunoassay biosensors that can be read with NFC-enabled devices, which will make healthcare and consumer diagnostics more affordable and accessible to all worldwide. These products and services will revolutionize not only medical applications, but also location-based services and the detection of environmental threats in homes and workplaces. Gentag’s first wireless sensor network patent was filed in 1997. All Gentag NFC patents are held by Altivera, LLC, a Maryland company operated by Gentag and owned by its shareholders. For more information, visit http://www.gentag.com and follow Gentag on Twitter (@gentagInc).

    For licensing rights under the joint Mayo-Gentag agreement, please contact:

    Bruce R. Kline
    Technology Licensing Manager II
    Mayo Clinic Ventures
    200 First Street SW
    Rochester, MN 55905
    Phone: 507-266-4586
    Fax: 507-284-5410
    Email: kline.bruce1@mayo.edu

    John P. Peeters, Ph.D.
    President and CEO
    Gentag, Inc.
    3299 K Street, NW, Suite 100
    Washington, D.C. 20007
    Phone: 240-994-2236
    Fax: 301-913-0350
    Email: john.peeters@gentag.com

    Media Contacts

    Brian Kilen, Mayo Clinic
    507-284-5005
    newsbureau@mayo.edu

    15
  • Welch Allyn and Gentag Wearable Medical Device Deal Announced

    October 28, 2014

    Skaneateles, NY, and Washington, DC, October 28, 2014 — Welch Allyn, a leading medical diagnostic device company that delivers pragmatic innovation at the point of care, and Gentag, Inc., a pioneer in disposable biosensors that can be read with near field communication (NFC) devices, announced today that they have entered into a strategic development agreement. Under the terms of the agreement, Welch Allyn and Gentag will bring to market near field communication technology for medical devices and sensors.

    The partnership with Gentag enables Welch Allyn to continue providing innovative solutions in medical settings, and NFC will allow the extension of these technologies for remote patient monitoring worldwide.

    “This collaborative opportunity will enable Welch Allyn to provide clinicians with smart monitoring solutions and improve patient access to cutting edge diagnostics,” said Welch Allyn President and CEO, Stephen Meyer.

    With Gentag’s NFC technology, it becomes possible to integrate ultrathin battery-less wireless sensors into various medical diagnostic applications. Sending patient measurement data wirelessly via near field communications will open up significant opportunities for workflow efficiency gains and faster availability of clinical information in the Electronic Health Record.

    “We are delighted by the partnership with Welch Allyn,” said Gentag CEO, John Peeters. “Welch Allyn has the knowledge, expertise and global market reach that will allow the globalization of NFC technologies in medical diagnostic settings. By combining our intellectual property and technology portfolios with Welch Allyn, we feel that patients will be better served by the worldwide availability of high quality wireless medical devices.”

    About Welch Allyn, Inc.

    Since 1915 Welch Allyn has brought a unique perspective to developing diagnostic solutions by combining pragmatic knowledge with a visionary spirit of innovation and ongoing improvement. As a leading global manufacturer of physical examination instruments and accessories and EMR-connected vital signs and cardiac monitoring solutions, the company has a steadfast commitment to delivering superlative medical products, services and solutions that help healthcare professionals provide better care for their patients. Welch Allyn is headquartered in Skaneateles Falls, N.Y. (USA) and employs more than 2,600 people in 26 different countries. Visit www.welchallyn.com for more information. Like us on Facebook and follow us on Twitter.

    About Gentag

    Gentag, Inc. is pioneering the use of disposable, ultrathin wearable and immunoassay biosensors that can be read with NFC-enabled devices, which will make healthcare and consumer diagnostics more affordable and accessible to all worldwide. The company’s groundbreaking work will revolutionize not only medical applications, but also location-based services and the detection of environmental threats in homes and workplaces. Gentag’s first wireless sensor network patent was filed in 1997. All Gentag NFC patents are held by Altivera, LLC, a Maryland company operated by Gentag and owned by its shareholders. Gentag’s powerful IP and partnerships are at work for a smarter, more connected world. For more information, visit www.gentag.com and follow Gentag on Twitter (@gentagInc).

    16
  • Wearables for Diagnostics: Gentag’s Disposable NFC Biomarker Patent Receives Notice of Allowance from the European Patent Office

    September 9, 2014

    WASHINGTON, DC Sept. 9, 2014 – Gentag, Inc. is pleased to announce that it has been granted a new, additional allowance for its patents in Europe. This allowance, granted by the European Patent Office, further enhances the company’s already significant intellectual property holdings of near field communication (NFC) mobile phone sensor technologies and complements its disposable wearable NFC sensor patent portfolio.

    The new patent covers quantitative diagnostic tests that can be carried out anywhere – no lab, or costly lab work, needed – using NFC-enabled mobile phones. Multiple diagnostic tests are possible using just a single drop of blood or urine. The new Gentag patent allowance covers the combination of NFC sensor chips and immunoassays, enabling virtually any biomarker test to be conducted with an NFC mobile phone. Biomarkers, tiny biological “signature” molecules, indicate the presence of specific proteins, diseases or medical conditions, including cancer.

    This platform technology, which can be tailored to measure almost any protein or biomarker, is printable and disposable. Examples of applications include: on-the-spot detection of pathogens, allergens in foods (e.g. peanuts) or the environment, and problematic drug interactions. Because of its low cost and ease of use, the technology could revolutionize diagnostics. “We believe that the combination of the well tested lateral flow immunoassay technology with new proprietary chemistries, custom monoclonal antibodies and a custom NFC sensor will allow accurate quantitative diagnostic testing to become available to everyone with a cell phone,” stated Dr. John P. Peeters, Gentag’s founder and Chief Executive, and an expert on biomarkers.

    Gentag’s early NFC patents, filed in 2003 and 2004, address the uses of disposable NFC sensor devices, including wearable skin patches and associated NFC readers in devices including mobile phones. The new allowance will complement the recently announced NFC diagnostic skin patch patents that are currently issuing in Europe. The Gentag NFC patents will issue in thirty countries including Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Germany, Estonia, Finland, France, Greece, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Monaco, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, Spain, Switzerland, Turkey and the United Kingdom.

    With the Gentag technologies, it becomes possible to integrate ultrathin, battery-less wireless sensors into disposable diagnostic tests or devices, such as NFC skin patches or immunoassays, allowing consumers and the medical community to conduct on-the-spot tests in multi-billion dollar markets such as fever monitoring, diabetes monitoring, drug interactions, post-surgery monitoring, obesity and weight management. Gentag’s core suite of patented technologies covers advanced geolocation; environmental genomics, including NFC immunoassays; NFC diagnostic skin patches; and BAN sensor networks for the Internet of Things (IoT).

    About Gentag

    Gentag is pioneering the use of disposable, ultrathin wearable and immunoassay biosensors that can be read with NFC-enabled devices, which will make healthcare and consumer diagnostics more affordable and accessible to all worldwide. The company’s groundbreaking work will revolutionize not only medical applications, but also location-based services and the detection of environmental threats in food, homes and workplaces everywhere. Gentag’s first wireless sensor network patent was filed in 1997. All Gentag NFC patents are held by Altivera, LLC, a Maryland company operated by Gentag and owned by its shareholders.

    Gentag’s powerful IP and partnerships are at work for a smarter, more connected world.

    For more information, visit http://gentag.com/ and follow Gentag on Twitter (@gentagInc).

    21